30-Day Mortality after Palliative Radiotherapy

Palliative radiotherapy (PRT) is a well-established treatment option for the palliation of symptoms related to advanced cancer. Common indications for PRT include pain and fracture prophylaxis from bone metastases, hemostasis, and neurological symptoms from spinal cord compression and/or brain metastases. Due to possible short term side effects and the fact that radiation often requires several weeks for full effect, many have cautioned its use in patients with a mortality estimate of < 30 days. Recently a large meta-analysis was published in the Green Journal which included 42 studies and 88,516 patients with advanced cancer who received PRT (Kutzko et al….

Continue reading

Now accepting nominations!

SPRO is pleased to offer two awards for individuals who have made notable contributions to the field of palliative radiation oncology through clinical care, patient advocacy, education, or research. Lifetime Service Award This award recognizes an individual whose service to the field over a period of a decade or more has resulted in an indelible transformation and advancement of the field of palliative radiation oncology. Rising Star Award This award recognizes an individual who is either a trainee or within the first two years of an academic appointment whose work shows notable promise to be transformative to the field of…

Continue reading

Congratulations to Dr. Tracy Balboni!

ASCO honors Dr. Tracy Balboni with the 2021 Walther Cancer Foundation Palliative and Supportive Care in Oncology Endowed Award. Dr. Tracy Balboni, MD, MPH, FAAHPM, was honored with the 2021 Walter Cancer Foundation Palliative and Supportive Care in Oncology Endowed Award.  Established in 2017, this award recognizes a leader who has made a significant contribution to palliative and supportive care in oncology through the prevention, assessment and management of cancer- and treatment-related suffering. Dr. Balboni is a Professor of Radiation Oncology at Harvard Medical School, Program Director of the Harvard Radiation Oncology Program, and Clinical Director of the Dana-Farber/Brigham and…

Continue reading